BioNTech Names Ex-Sobi CEO Oelkers to Replace Sahin
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- BioNTech named Guido Oelkers, formerly CEO of Swedish biopharma Sobi, as its new CEO on Monday
- Oelkers will replace Ugur Sahin, who along with co-founder and chief medical officer Özlem Türeci (Sahin's wife) announced in March they would depart BioNTech to lead a new biotech focused on developing mRNA medicines
- Oelkers brings more than 30 years of biopharma experience and is set to start by Feb. 1, 2027
- Oelkers said he would continue BioNTech's stated goal of becoming a global company with multiple approved medicines by 2030
- The CEO swap comes as BioNTech continues its strategic shift from Covid-19 vaccine development to oncology
Why it matters: BioNTech is handing the reins to a career commercial biopharma operator rather than another scientist, signaling that the company's next phase — pivoting from pandemic-scale vaccine manufacturing to a diversified oncology pipeline — will be judged on late-stage clinical execution and global launches. With Sahin and Türeci leaving for a new mRNA-focused startup, the mRNA pioneers are effectively choosing the science over the company they scaled during Covid-19.
Ask SkimNews
